EP 2 265 251 B1 relates to pharmaceutical compositions that contain surfactant concentrations that promote bioavailability of a therapeutic agent in the composition.
Brief outline of the case
In the course of first appeal proceedings, cf. T 2431/17, the opponents objected for the first time that the priority was invalid for lack of entitlement,